nodes	percent_of_prediction	percent_of_DWPC	metapath
Ponatinib—ABCG2—Nelfinavir—acquired immunodeficiency syndrome	0.0311	0.0501	CbGbCtD
Ponatinib—ABCG2—Saquinavir—acquired immunodeficiency syndrome	0.0281	0.0453	CbGbCtD
Ponatinib—ABCG2—Ritonavir—acquired immunodeficiency syndrome	0.0281	0.0453	CbGbCtD
Ponatinib—ABCG2—Zidovudine—acquired immunodeficiency syndrome	0.027	0.0434	CbGbCtD
Ponatinib—CYP3A5—Nevirapine—acquired immunodeficiency syndrome	0.0227	0.0366	CbGbCtD
Ponatinib—ABCG2—Lamivudine—acquired immunodeficiency syndrome	0.0209	0.0336	CbGbCtD
Ponatinib—CYP3A5—Amprenavir—acquired immunodeficiency syndrome	0.0206	0.0331	CbGbCtD
Ponatinib—CYP3A5—Delavirdine—acquired immunodeficiency syndrome	0.0206	0.0331	CbGbCtD
Ponatinib—CYP2C8—Delavirdine—acquired immunodeficiency syndrome	0.0198	0.0318	CbGbCtD
Ponatinib—CYP2C8—Amprenavir—acquired immunodeficiency syndrome	0.0198	0.0318	CbGbCtD
Ponatinib—CYP3A5—Indinavir—acquired immunodeficiency syndrome	0.0177	0.0286	CbGbCtD
Ponatinib—CYP3A5—Nelfinavir—acquired immunodeficiency syndrome	0.0172	0.0278	CbGbCtD
Ponatinib—CYP3A5—Saquinavir—acquired immunodeficiency syndrome	0.0156	0.0251	CbGbCtD
Ponatinib—CYP3A5—Ritonavir—acquired immunodeficiency syndrome	0.0156	0.0251	CbGbCtD
Ponatinib—CYP2C8—Ritonavir—acquired immunodeficiency syndrome	0.015	0.0241	CbGbCtD
Ponatinib—CYP2C8—Saquinavir—acquired immunodeficiency syndrome	0.015	0.0241	CbGbCtD
Ponatinib—CYP2D6—Efavirenz—acquired immunodeficiency syndrome	0.0148	0.0239	CbGbCtD
Ponatinib—ABCB1—Lopinavir—acquired immunodeficiency syndrome	0.0148	0.0238	CbGbCtD
Ponatinib—CYP2C8—Zidovudine—acquired immunodeficiency syndrome	0.0144	0.0231	CbGbCtD
Ponatinib—CYP2D6—Nevirapine—acquired immunodeficiency syndrome	0.0139	0.0225	CbGbCtD
Ponatinib—CYP2D6—Lopinavir—acquired immunodeficiency syndrome	0.0139	0.0225	CbGbCtD
Ponatinib—ABCB1—Amprenavir—acquired immunodeficiency syndrome	0.0134	0.0216	CbGbCtD
Ponatinib—CYP2D6—Amprenavir—acquired immunodeficiency syndrome	0.0126	0.0203	CbGbCtD
Ponatinib—CYP2D6—Delavirdine—acquired immunodeficiency syndrome	0.0126	0.0203	CbGbCtD
Ponatinib—ABCB1—Indinavir—acquired immunodeficiency syndrome	0.0115	0.0186	CbGbCtD
Ponatinib—ABCB1—Nelfinavir—acquired immunodeficiency syndrome	0.0112	0.0181	CbGbCtD
Ponatinib—CYP2D6—Indinavir—acquired immunodeficiency syndrome	0.0109	0.0175	CbGbCtD
Ponatinib—CYP2D6—Nelfinavir—acquired immunodeficiency syndrome	0.0106	0.017	CbGbCtD
Ponatinib—ABCB1—Ritonavir—acquired immunodeficiency syndrome	0.0101	0.0163	CbGbCtD
Ponatinib—ABCB1—Saquinavir—acquired immunodeficiency syndrome	0.0101	0.0163	CbGbCtD
Ponatinib—ABCB1—Zidovudine—acquired immunodeficiency syndrome	0.00972	0.0157	CbGbCtD
Ponatinib—CYP2D6—Ritonavir—acquired immunodeficiency syndrome	0.00955	0.0154	CbGbCtD
Ponatinib—CYP2D6—Saquinavir—acquired immunodeficiency syndrome	0.00955	0.0154	CbGbCtD
Ponatinib—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.00943	0.0152	CbGbCtD
Ponatinib—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.00886	0.0143	CbGbCtD
Ponatinib—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.00886	0.0143	CbGbCtD
Ponatinib—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.00802	0.0129	CbGbCtD
Ponatinib—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.00802	0.0129	CbGbCtD
Ponatinib—ABCB1—Lamivudine—acquired immunodeficiency syndrome	0.00752	0.0121	CbGbCtD
Ponatinib—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.00692	0.0111	CbGbCtD
Ponatinib—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.00672	0.0108	CbGbCtD
Ponatinib—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.00607	0.00979	CbGbCtD
Ponatinib—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.00607	0.00979	CbGbCtD
Ponatinib—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.00582	0.00938	CbGbCtD
Ponatinib—LYN—blood plasma—acquired immunodeficiency syndrome	0.00266	0.0266	CbGeAlD
Ponatinib—BCR—blood plasma—acquired immunodeficiency syndrome	0.00229	0.0229	CbGeAlD
Ponatinib—FLT3—blood plasma—acquired immunodeficiency syndrome	0.00228	0.0228	CbGeAlD
Ponatinib—TEK—endothelium—acquired immunodeficiency syndrome	0.00187	0.0187	CbGeAlD
Ponatinib—SRC—endothelium—acquired immunodeficiency syndrome	0.00166	0.0166	CbGeAlD
Ponatinib—KDR—endothelium—acquired immunodeficiency syndrome	0.00153	0.0153	CbGeAlD
Ponatinib—FGFR4—digestive system—acquired immunodeficiency syndrome	0.00149	0.0149	CbGeAlD
Ponatinib—SRC—blood plasma—acquired immunodeficiency syndrome	0.00148	0.0148	CbGeAlD
Ponatinib—FGFR4—blood—acquired immunodeficiency syndrome	0.00142	0.0142	CbGeAlD
Ponatinib—KDR—blood plasma—acquired immunodeficiency syndrome	0.00136	0.0136	CbGeAlD
Ponatinib—KIT—endothelium—acquired immunodeficiency syndrome	0.00136	0.0136	CbGeAlD
Ponatinib—FGFR3—skin of body—acquired immunodeficiency syndrome	0.00127	0.0127	CbGeAlD
Ponatinib—FGFR4—lung—acquired immunodeficiency syndrome	0.00125	0.0125	CbGeAlD
Ponatinib—KIT—blood plasma—acquired immunodeficiency syndrome	0.0012	0.012	CbGeAlD
Ponatinib—FGFR4—nervous system—acquired immunodeficiency syndrome	0.00115	0.0115	CbGeAlD
Ponatinib—FGFR4—central nervous system—acquired immunodeficiency syndrome	0.00111	0.0111	CbGeAlD
Ponatinib—LYN—lymphoid tissue—acquired immunodeficiency syndrome	0.00104	0.0104	CbGeAlD
Ponatinib—LYN—blood—acquired immunodeficiency syndrome	0.000975	0.00975	CbGeAlD
Ponatinib—FGFR3—spinal cord—acquired immunodeficiency syndrome	0.000935	0.00935	CbGeAlD
Ponatinib—BCR—lymphoid tissue—acquired immunodeficiency syndrome	0.000892	0.00892	CbGeAlD
Ponatinib—FLT3—lymphoid tissue—acquired immunodeficiency syndrome	0.000886	0.00886	CbGeAlD
Ponatinib—FGFR4—brain—acquired immunodeficiency syndrome	0.000882	0.00882	CbGeAlD
Ponatinib—FGFR4—lymph node—acquired immunodeficiency syndrome	0.000853	0.00853	CbGeAlD
Ponatinib—FGFR3—lung—acquired immunodeficiency syndrome	0.000851	0.00851	CbGeAlD
Ponatinib—BCR—blood—acquired immunodeficiency syndrome	0.00084	0.00839	CbGeAlD
Ponatinib—FLT3—blood—acquired immunodeficiency syndrome	0.000834	0.00834	CbGeAlD
Ponatinib—FGFR2—skin of body—acquired immunodeficiency syndrome	0.000834	0.00833	CbGeAlD
Ponatinib—BCR—bone marrow—acquired immunodeficiency syndrome	0.000812	0.00812	CbGeAlD
Ponatinib—BCR—spinal cord—acquired immunodeficiency syndrome	0.000809	0.00809	CbGeAlD
Ponatinib—SRC—retina—acquired immunodeficiency syndrome	0.000809	0.00809	CbGeAlD
Ponatinib—FLT3—bone marrow—acquired immunodeficiency syndrome	0.000807	0.00807	CbGeAlD
Ponatinib—LYN—nervous system—acquired immunodeficiency syndrome	0.000792	0.00792	CbGeAlD
Ponatinib—FGFR3—nervous system—acquired immunodeficiency syndrome	0.000788	0.00788	CbGeAlD
Ponatinib—BCR—vagina—acquired immunodeficiency syndrome	0.000778	0.00778	CbGeAlD
Ponatinib—LYN—central nervous system—acquired immunodeficiency syndrome	0.000762	0.00762	CbGeAlD
Ponatinib—FGFR3—central nervous system—acquired immunodeficiency syndrome	0.000758	0.00758	CbGeAlD
Ponatinib—KDR—retina—acquired immunodeficiency syndrome	0.000744	0.00744	CbGeAlD
Ponatinib—BCR—lung—acquired immunodeficiency syndrome	0.000736	0.00736	CbGeAlD
Ponatinib—FLT3—lung—acquired immunodeficiency syndrome	0.000731	0.00731	CbGeAlD
Ponatinib—FGFR1—spinal cord—acquired immunodeficiency syndrome	0.00072	0.0072	CbGeAlD
Ponatinib—RET—lymphoid tissue—acquired immunodeficiency syndrome	0.00071	0.0071	CbGeAlD
Ponatinib—SRC—skin of body—acquired immunodeficiency syndrome	0.00071	0.0071	CbGeAlD
Ponatinib—RET—digestive system—acquired immunodeficiency syndrome	0.000702	0.00702	CbGeAlD
Ponatinib—FGFR1—vagina—acquired immunodeficiency syndrome	0.000693	0.00692	CbGeAlD
Ponatinib—ABCB11—digestive system—acquired immunodeficiency syndrome	0.000685	0.00685	CbGeAlD
Ponatinib—BCR—nervous system—acquired immunodeficiency syndrome	0.000682	0.00682	CbGeAlD
Ponatinib—CYP2C8—blood plasma—acquired immunodeficiency syndrome	0.00068	0.0068	CbGeAlD
Ponatinib—LCK—blood—acquired immunodeficiency syndrome	0.000669	0.00668	CbGeAlD
Ponatinib—RET—blood—acquired immunodeficiency syndrome	0.000669	0.00668	CbGeAlD
Ponatinib—FGFR2—digestive system—acquired immunodeficiency syndrome	0.000667	0.00667	CbGeAlD
Ponatinib—BCR—central nervous system—acquired immunodeficiency syndrome	0.000656	0.00656	CbGeAlD
Ponatinib—FGFR1—lung—acquired immunodeficiency syndrome	0.000655	0.00655	CbGeAlD
Ponatinib—TEK—lymphoid tissue—acquired immunodeficiency syndrome	0.000647	0.00647	CbGeAlD
Ponatinib—LCK—bone marrow—acquired immunodeficiency syndrome	0.000647	0.00647	CbGeAlD
Ponatinib—RET—spinal cord—acquired immunodeficiency syndrome	0.000644	0.00644	CbGeAlD
Ponatinib—FGFR2—blood—acquired immunodeficiency syndrome	0.000635	0.00635	CbGeAlD
Ponatinib—LCK—vagina—acquired immunodeficiency syndrome	0.00062	0.0062	CbGeAlD
Ponatinib—CYP3A5—blood plasma—acquired immunodeficiency syndrome	0.000614	0.00613	CbGeAlD
Ponatinib—FGFR2—spinal cord—acquired immunodeficiency syndrome	0.000612	0.00612	CbGeAlD
Ponatinib—TEK—blood—acquired immunodeficiency syndrome	0.000609	0.00609	CbGeAlD
Ponatinib—LYN—brain—acquired immunodeficiency syndrome	0.000605	0.00605	CbGeAlD
Ponatinib—FGFR3—brain—acquired immunodeficiency syndrome	0.000602	0.00602	CbGeAlD
Ponatinib—TEK—spinal cord—acquired immunodeficiency syndrome	0.000587	0.00587	CbGeAlD
Ponatinib—PDGFRA—lymphoid tissue—acquired immunodeficiency syndrome	0.000586	0.00586	CbGeAlD
Ponatinib—LCK—lung—acquired immunodeficiency syndrome	0.000586	0.00586	CbGeAlD
Ponatinib—PDGFRA—digestive system—acquired immunodeficiency syndrome	0.000579	0.00579	CbGeAlD
Ponatinib—KIT—skin of body—acquired immunodeficiency syndrome	0.000579	0.00579	CbGeAlD
Ponatinib—SRC—lymphoid tissue—acquired immunodeficiency syndrome	0.000575	0.00575	CbGeAlD
Ponatinib—ABL1—retina—acquired immunodeficiency syndrome	0.000574	0.00574	CbGeAlD
Ponatinib—SRC—digestive system—acquired immunodeficiency syndrome	0.000568	0.00568	CbGeAlD
Ponatinib—FGFR2—lung—acquired immunodeficiency syndrome	0.000557	0.00557	CbGeAlD
Ponatinib—PDGFRA—blood—acquired immunodeficiency syndrome	0.000552	0.00552	CbGeAlD
Ponatinib—RET—nervous system—acquired immunodeficiency syndrome	0.000543	0.00543	CbGeAlD
Ponatinib—SRC—blood—acquired immunodeficiency syndrome	0.000541	0.00541	CbGeAlD
Ponatinib—TEK—lung—acquired immunodeficiency syndrome	0.000534	0.00534	CbGeAlD
Ponatinib—PDGFRA—spinal cord—acquired immunodeficiency syndrome	0.000532	0.00531	CbGeAlD
Ponatinib—KDR—lymphoid tissue—acquired immunodeficiency syndrome	0.000529	0.00529	CbGeAlD
Ponatinib—RET—central nervous system—acquired immunodeficiency syndrome	0.000523	0.00522	CbGeAlD
Ponatinib—KDR—digestive system—acquired immunodeficiency syndrome	0.000522	0.00522	CbGeAlD
Ponatinib—SRC—spinal cord—acquired immunodeficiency syndrome	0.000521	0.00521	CbGeAlD
Ponatinib—BCR—brain—acquired immunodeficiency syndrome	0.000521	0.00521	CbGeAlD
Ponatinib—FGFR2—nervous system—acquired immunodeficiency syndrome	0.000516	0.00516	CbGeAlD
Ponatinib—PDGFRA—vagina—acquired immunodeficiency syndrome	0.000511	0.00511	CbGeAlD
Ponatinib—ABL1—skin of body—acquired immunodeficiency syndrome	0.000504	0.00504	CbGeAlD
Ponatinib—BCR—lymph node—acquired immunodeficiency syndrome	0.000503	0.00503	CbGeAlD
Ponatinib—FLT3—lymph node—acquired immunodeficiency syndrome	0.0005	0.005	CbGeAlD
Ponatinib—KDR—blood—acquired immunodeficiency syndrome	0.000498	0.00498	CbGeAlD
Ponatinib—FGFR2—central nervous system—acquired immunodeficiency syndrome	0.000496	0.00496	CbGeAlD
Ponatinib—TEK—nervous system—acquired immunodeficiency syndrome	0.000494	0.00494	CbGeAlD
Ponatinib—PDGFRA—lung—acquired immunodeficiency syndrome	0.000484	0.00484	CbGeAlD
Ponatinib—KDR—bone marrow—acquired immunodeficiency syndrome	0.000482	0.00482	CbGeAlD
Ponatinib—KDR—spinal cord—acquired immunodeficiency syndrome	0.00048	0.00479	CbGeAlD
Ponatinib—TEK—central nervous system—acquired immunodeficiency syndrome	0.000476	0.00476	CbGeAlD
Ponatinib—SRC—lung—acquired immunodeficiency syndrome	0.000474	0.00474	CbGeAlD
Ponatinib—KIT—lymphoid tissue—acquired immunodeficiency syndrome	0.000469	0.00469	CbGeAlD
Ponatinib—FGFR1—brain—acquired immunodeficiency syndrome	0.000464	0.00463	CbGeAlD
Ponatinib—KIT—digestive system—acquired immunodeficiency syndrome	0.000463	0.00463	CbGeAlD
Ponatinib—KDR—vagina—acquired immunodeficiency syndrome	0.000461	0.00461	CbGeAlD
Ponatinib—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.00046	0.0046	CbGeAlD
Ponatinib—CYP2D6—blood plasma—acquired immunodeficiency syndrome	0.000453	0.00453	CbGeAlD
Ponatinib—FGFR1—lymph node—acquired immunodeficiency syndrome	0.000448	0.00448	CbGeAlD
Ponatinib—PDGFRA—nervous system—acquired immunodeficiency syndrome	0.000448	0.00448	CbGeAlD
Ponatinib—KIT—blood—acquired immunodeficiency syndrome	0.000441	0.00441	CbGeAlD
Ponatinib—SRC—nervous system—acquired immunodeficiency syndrome	0.000439	0.00439	CbGeAlD
Ponatinib—KDR—lung—acquired immunodeficiency syndrome	0.000436	0.00436	CbGeAlD
Ponatinib—PDGFRA—central nervous system—acquired immunodeficiency syndrome	0.000431	0.00431	CbGeAlD
Ponatinib—KIT—bone marrow—acquired immunodeficiency syndrome	0.000427	0.00427	CbGeAlD
Ponatinib—KIT—spinal cord—acquired immunodeficiency syndrome	0.000425	0.00425	CbGeAlD
Ponatinib—SRC—central nervous system—acquired immunodeficiency syndrome	0.000423	0.00423	CbGeAlD
Ponatinib—RET—brain—acquired immunodeficiency syndrome	0.000415	0.00415	CbGeAlD
Ponatinib—KIT—vagina—acquired immunodeficiency syndrome	0.000409	0.00409	CbGeAlD
Ponatinib—ABL1—lymphoid tissue—acquired immunodeficiency syndrome	0.000408	0.00408	CbGeAlD
Ponatinib—KDR—nervous system—acquired immunodeficiency syndrome	0.000404	0.00404	CbGeAlD
Ponatinib—ABL1—digestive system—acquired immunodeficiency syndrome	0.000403	0.00403	CbGeAlD
Ponatinib—LCK—lymph node—acquired immunodeficiency syndrome	0.000401	0.00401	CbGeAlD
Ponatinib—RET—lymph node—acquired immunodeficiency syndrome	0.000401	0.00401	CbGeAlD
Ponatinib—FGFR2—brain—acquired immunodeficiency syndrome	0.000394	0.00394	CbGeAlD
Ponatinib—KDR—central nervous system—acquired immunodeficiency syndrome	0.000389	0.00389	CbGeAlD
Ponatinib—KIT—lung—acquired immunodeficiency syndrome	0.000387	0.00387	CbGeAlD
Ponatinib—ABL1—blood—acquired immunodeficiency syndrome	0.000384	0.00384	CbGeAlD
Ponatinib—TEK—brain—acquired immunodeficiency syndrome	0.000378	0.00378	CbGeAlD
Ponatinib—ABL1—bone marrow—acquired immunodeficiency syndrome	0.000372	0.00371	CbGeAlD
Ponatinib—ABL1—spinal cord—acquired immunodeficiency syndrome	0.00037	0.0037	CbGeAlD
Ponatinib—TEK—lymph node—acquired immunodeficiency syndrome	0.000365	0.00365	CbGeAlD
Ponatinib—KIT—nervous system—acquired immunodeficiency syndrome	0.000358	0.00358	CbGeAlD
Ponatinib—ABL1—vagina—acquired immunodeficiency syndrome	0.000356	0.00356	CbGeAlD
Ponatinib—KIT—central nervous system—acquired immunodeficiency syndrome	0.000345	0.00345	CbGeAlD
Ponatinib—PDGFRA—brain—acquired immunodeficiency syndrome	0.000342	0.00342	CbGeAlD
Ponatinib—ABL1—lung—acquired immunodeficiency syndrome	0.000337	0.00337	CbGeAlD
Ponatinib—SRC—brain—acquired immunodeficiency syndrome	0.000336	0.00336	CbGeAlD
Ponatinib—PDGFRA—lymph node—acquired immunodeficiency syndrome	0.000331	0.00331	CbGeAlD
Ponatinib—ABCB1—blood plasma—acquired immunodeficiency syndrome	0.000326	0.00326	CbGeAlD
Ponatinib—SRC—lymph node—acquired immunodeficiency syndrome	0.000324	0.00324	CbGeAlD
Ponatinib—ABL1—nervous system—acquired immunodeficiency syndrome	0.000312	0.00312	CbGeAlD
Ponatinib—KDR—brain—acquired immunodeficiency syndrome	0.000309	0.00309	CbGeAlD
Ponatinib—ABL1—central nervous system—acquired immunodeficiency syndrome	0.0003	0.003	CbGeAlD
Ponatinib—KDR—lymph node—acquired immunodeficiency syndrome	0.000298	0.00298	CbGeAlD
Ponatinib—KIT—brain—acquired immunodeficiency syndrome	0.000274	0.00274	CbGeAlD
Ponatinib—KIT—lymph node—acquired immunodeficiency syndrome	0.000264	0.00264	CbGeAlD
Ponatinib—CYP2C8—blood—acquired immunodeficiency syndrome	0.000249	0.00249	CbGeAlD
Ponatinib—ABCG2—blood—acquired immunodeficiency syndrome	0.000242	0.00242	CbGeAlD
Ponatinib—ABL1—brain—acquired immunodeficiency syndrome	0.000238	0.00238	CbGeAlD
Ponatinib—CYP3A5—digestive system—acquired immunodeficiency syndrome	0.000236	0.00236	CbGeAlD
Ponatinib—ABCG2—bone marrow—acquired immunodeficiency syndrome	0.000234	0.00234	CbGeAlD
Ponatinib—ABCG2—spinal cord—acquired immunodeficiency syndrome	0.000233	0.00233	CbGeAlD
Ponatinib—CYP2C8—vagina—acquired immunodeficiency syndrome	0.000231	0.00231	CbGeAlD
Ponatinib—ABL1—lymph node—acquired immunodeficiency syndrome	0.00023	0.0023	CbGeAlD
Ponatinib—CYP3A5—blood—acquired immunodeficiency syndrome	0.000225	0.00225	CbGeAlD
Ponatinib—ABCG2—vagina—acquired immunodeficiency syndrome	0.000224	0.00224	CbGeAlD
Ponatinib—ABCG2—lung—acquired immunodeficiency syndrome	0.000212	0.00212	CbGeAlD
Ponatinib—CYP3A5—vagina—acquired immunodeficiency syndrome	0.000208	0.00208	CbGeAlD
Ponatinib—CYP3A5—lung—acquired immunodeficiency syndrome	0.000197	0.00197	CbGeAlD
Ponatinib—ABCB1—retina—acquired immunodeficiency syndrome	0.000178	0.00178	CbGeAlD
Ponatinib—CYP3A4—digestive system—acquired immunodeficiency syndrome	0.000177	0.00177	CbGeAlD
Ponatinib—CYP2D6—digestive system—acquired immunodeficiency syndrome	0.000174	0.00174	CbGeAlD
Ponatinib—CYP3A4—blood—acquired immunodeficiency syndrome	0.000169	0.00169	CbGeAlD
Ponatinib—CYP2D6—blood—acquired immunodeficiency syndrome	0.000166	0.00166	CbGeAlD
Ponatinib—CYP2C8—brain—acquired immunodeficiency syndrome	0.000155	0.00154	CbGeAlD
Ponatinib—ABCG2—brain—acquired immunodeficiency syndrome	0.00015	0.0015	CbGeAlD
Ponatinib—ABCG2—lymph node—acquired immunodeficiency syndrome	0.000145	0.00145	CbGeAlD
Ponatinib—Alopecia—Lamivudine—acquired immunodeficiency syndrome	0.000142	0.000669	CcSEcCtD
Ponatinib—Back pain—Saquinavir—acquired immunodeficiency syndrome	0.000142	0.000668	CcSEcCtD
Ponatinib—Muscle spasms—Saquinavir—acquired immunodeficiency syndrome	0.000141	0.000664	CcSEcCtD
Ponatinib—Anaemia—Ritonavir—acquired immunodeficiency syndrome	0.000141	0.000663	CcSEcCtD
Ponatinib—Dyspepsia—Zidovudine—acquired immunodeficiency syndrome	0.00014	0.000663	CcSEcCtD
Ponatinib—Arthralgia—Delavirdine—acquired immunodeficiency syndrome	0.00014	0.000661	CcSEcCtD
Ponatinib—Myalgia—Delavirdine—acquired immunodeficiency syndrome	0.00014	0.000661	CcSEcCtD
Ponatinib—Malnutrition—Lamivudine—acquired immunodeficiency syndrome	0.00014	0.000659	CcSEcCtD
Ponatinib—Erythema—Lamivudine—acquired immunodeficiency syndrome	0.00014	0.000659	CcSEcCtD
Ponatinib—Decreased appetite—Zidovudine—acquired immunodeficiency syndrome	0.000139	0.000655	CcSEcCtD
Ponatinib—Nausea—Amprenavir—acquired immunodeficiency syndrome	0.000138	0.000651	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Zidovudine—acquired immunodeficiency syndrome	0.000138	0.000651	CcSEcCtD
Ponatinib—Fatigue—Zidovudine—acquired immunodeficiency syndrome	0.000138	0.00065	CcSEcCtD
Ponatinib—Nervous system disorder—Efavirenz—acquired immunodeficiency syndrome	0.000138	0.000649	CcSEcCtD
Ponatinib—Thrombocytopenia—Efavirenz—acquired immunodeficiency syndrome	0.000137	0.000648	CcSEcCtD
Ponatinib—CYP3A4—nervous system—acquired immunodeficiency syndrome	0.000137	0.00137	CbGeAlD
Ponatinib—Dry mouth—Delavirdine—acquired immunodeficiency syndrome	0.000137	0.000646	CcSEcCtD
Ponatinib—Pain—Zidovudine—acquired immunodeficiency syndrome	0.000136	0.000644	CcSEcCtD
Ponatinib—Constipation—Zidovudine—acquired immunodeficiency syndrome	0.000136	0.000644	CcSEcCtD
Ponatinib—Asthenia—Nevirapine—acquired immunodeficiency syndrome	0.000136	0.000644	CcSEcCtD
Ponatinib—Skin disorder—Efavirenz—acquired immunodeficiency syndrome	0.000136	0.000643	CcSEcCtD
Ponatinib—Leukopenia—Ritonavir—acquired immunodeficiency syndrome	0.000136	0.000642	CcSEcCtD
Ponatinib—Hyperhidrosis—Efavirenz—acquired immunodeficiency syndrome	0.000136	0.00064	CcSEcCtD
Ponatinib—Anaemia—Saquinavir—acquired immunodeficiency syndrome	0.000135	0.000639	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Indinavir—acquired immunodeficiency syndrome	0.000135	0.000638	CcSEcCtD
Ponatinib—Back pain—Lamivudine—acquired immunodeficiency syndrome	0.000135	0.000637	CcSEcCtD
Ponatinib—CYP2D6—nervous system—acquired immunodeficiency syndrome	0.000135	0.00135	CbGeAlD
Ponatinib—Pruritus—Nevirapine—acquired immunodeficiency syndrome	0.000135	0.000635	CcSEcCtD
Ponatinib—Vomiting—Didanosine—acquired immunodeficiency syndrome	0.000134	0.000635	CcSEcCtD
Ponatinib—Insomnia—Indinavir—acquired immunodeficiency syndrome	0.000134	0.000634	CcSEcCtD
Ponatinib—Muscle spasms—Lamivudine—acquired immunodeficiency syndrome	0.000134	0.000634	CcSEcCtD
Ponatinib—Oedema—Delavirdine—acquired immunodeficiency syndrome	0.000134	0.000633	CcSEcCtD
Ponatinib—Rash—Didanosine—acquired immunodeficiency syndrome	0.000133	0.00063	CcSEcCtD
Ponatinib—Infection—Delavirdine—acquired immunodeficiency syndrome	0.000133	0.000629	CcSEcCtD
Ponatinib—Paraesthesia—Indinavir—acquired immunodeficiency syndrome	0.000133	0.000629	CcSEcCtD
Ponatinib—Dermatitis—Didanosine—acquired immunodeficiency syndrome	0.000133	0.000629	CcSEcCtD
Ponatinib—Cough—Ritonavir—acquired immunodeficiency syndrome	0.000133	0.000626	CcSEcCtD
Ponatinib—Headache—Didanosine—acquired immunodeficiency syndrome	0.000132	0.000626	CcSEcCtD
Ponatinib—Dyspnoea—Indinavir—acquired immunodeficiency syndrome	0.000132	0.000625	CcSEcCtD
Ponatinib—Asthenia—Nelfinavir—acquired immunodeficiency syndrome	0.000132	0.000624	CcSEcCtD
Ponatinib—CYP3A4—central nervous system—acquired immunodeficiency syndrome	0.000132	0.00132	CbGeAlD
Ponatinib—Asthenia—Stavudine—acquired immunodeficiency syndrome	0.000132	0.000622	CcSEcCtD
Ponatinib—Thrombocytopenia—Delavirdine—acquired immunodeficiency syndrome	0.000131	0.00062	CcSEcCtD
Ponatinib—Hypertension—Ritonavir—acquired immunodeficiency syndrome	0.000131	0.00062	CcSEcCtD
Ponatinib—Leukopenia—Saquinavir—acquired immunodeficiency syndrome	0.000131	0.000618	CcSEcCtD
Ponatinib—Dyspepsia—Indinavir—acquired immunodeficiency syndrome	0.000131	0.000617	CcSEcCtD
Ponatinib—Gastrointestinal pain—Zidovudine—acquired immunodeficiency syndrome	0.00013	0.000616	CcSEcCtD
Ponatinib—Skin disorder—Delavirdine—acquired immunodeficiency syndrome	0.00013	0.000615	CcSEcCtD
Ponatinib—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	0.00013	0.000615	CcSEcCtD
Ponatinib—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	0.00013	0.000614	CcSEcCtD
Ponatinib—Pruritus—Stavudine—acquired immunodeficiency syndrome	0.00013	0.000613	CcSEcCtD
Ponatinib—Asthenia—Abacavir—acquired immunodeficiency syndrome	0.00013	0.000613	CcSEcCtD
Ponatinib—CYP2D6—central nervous system—acquired immunodeficiency syndrome	0.00013	0.0013	CbGeAlD
Ponatinib—Hyperhidrosis—Delavirdine—acquired immunodeficiency syndrome	0.00013	0.000612	CcSEcCtD
Ponatinib—Arthralgia—Ritonavir—acquired immunodeficiency syndrome	0.000129	0.000611	CcSEcCtD
Ponatinib—Myalgia—Ritonavir—acquired immunodeficiency syndrome	0.000129	0.000611	CcSEcCtD
Ponatinib—Decreased appetite—Indinavir—acquired immunodeficiency syndrome	0.000129	0.000609	CcSEcCtD
Ponatinib—Anaemia—Lamivudine—acquired immunodeficiency syndrome	0.000129	0.000609	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	0.000129	0.000607	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	0.000128	0.000605	CcSEcCtD
Ponatinib—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.000128	0.000604	CcSEcCtD
Ponatinib—Fatigue—Indinavir—acquired immunodeficiency syndrome	0.000128	0.000604	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	0.000128	0.000603	CcSEcCtD
Ponatinib—Cough—Saquinavir—acquired immunodeficiency syndrome	0.000128	0.000603	CcSEcCtD
Ponatinib—Constipation—Indinavir—acquired immunodeficiency syndrome	0.000127	0.000599	CcSEcCtD
Ponatinib—Pain—Indinavir—acquired immunodeficiency syndrome	0.000127	0.000599	CcSEcCtD
Ponatinib—ABCB1—lymphoid tissue—acquired immunodeficiency syndrome	0.000127	0.00127	CbGeAlD
Ponatinib—Insomnia—Efavirenz—acquired immunodeficiency syndrome	0.000127	0.000599	CcSEcCtD
Ponatinib—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	0.000127	0.000598	CcSEcCtD
Ponatinib—Hypertension—Saquinavir—acquired immunodeficiency syndrome	0.000126	0.000596	CcSEcCtD
Ponatinib—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	0.000126	0.000596	CcSEcCtD
Ponatinib—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	0.000126	0.000596	CcSEcCtD
Ponatinib—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	0.000126	0.000595	CcSEcCtD
Ponatinib—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	0.000126	0.000595	CcSEcCtD
Ponatinib—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	0.000126	0.000593	CcSEcCtD
Ponatinib—Nausea—Didanosine—acquired immunodeficiency syndrome	0.000126	0.000593	CcSEcCtD
Ponatinib—ABCB1—digestive system—acquired immunodeficiency syndrome	0.000125	0.00125	CbGeAlD
Ponatinib—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	0.000125	0.00059	CcSEcCtD
Ponatinib—Leukopenia—Lamivudine—acquired immunodeficiency syndrome	0.000125	0.00059	CcSEcCtD
Ponatinib—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	0.000125	0.000588	CcSEcCtD
Ponatinib—Myalgia—Saquinavir—acquired immunodeficiency syndrome	0.000125	0.000588	CcSEcCtD
Ponatinib—Oedema—Ritonavir—acquired immunodeficiency syndrome	0.000124	0.000586	CcSEcCtD
Ponatinib—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	0.000124	0.000584	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	0.000124	0.000584	CcSEcCtD
Ponatinib—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	0.000123	0.000583	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	0.000122	0.000577	CcSEcCtD
Ponatinib—Imatinib—ALB—acquired immunodeficiency syndrome	0.000122	1	CrCbGaD
Ponatinib—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	0.000122	0.000576	CcSEcCtD
Ponatinib—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	0.000122	0.000575	CcSEcCtD
Ponatinib—Cough—Lamivudine—acquired immunodeficiency syndrome	0.000122	0.000575	CcSEcCtD
Ponatinib—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.000122	0.000575	CcSEcCtD
Ponatinib—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	0.000122	0.000574	CcSEcCtD
Ponatinib—Thrombocytopenia—Ritonavir—acquired immunodeficiency syndrome	0.000121	0.000574	CcSEcCtD
Ponatinib—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.000121	0.000573	CcSEcCtD
Ponatinib—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	0.000121	0.000573	CcSEcCtD
Ponatinib—Insomnia—Delavirdine—acquired immunodeficiency syndrome	0.000121	0.000573	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	0.000121	0.000572	CcSEcCtD
Ponatinib—Vomiting—Nevirapine—acquired immunodeficiency syndrome	0.000121	0.000571	CcSEcCtD
Ponatinib—Fatigue—Efavirenz—acquired immunodeficiency syndrome	0.000121	0.000571	CcSEcCtD
Ponatinib—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	0.000121	0.000569	CcSEcCtD
Ponatinib—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	0.00012	0.000569	CcSEcCtD
Ponatinib—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	0.00012	0.000566	CcSEcCtD
Ponatinib—Constipation—Efavirenz—acquired immunodeficiency syndrome	0.00012	0.000566	CcSEcCtD
Ponatinib—Pain—Efavirenz—acquired immunodeficiency syndrome	0.00012	0.000566	CcSEcCtD
Ponatinib—Rash—Nevirapine—acquired immunodeficiency syndrome	0.00012	0.000566	CcSEcCtD
Ponatinib—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	0.00012	0.000566	CcSEcCtD
Ponatinib—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	0.00012	0.000565	CcSEcCtD
Ponatinib—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.00012	0.000565	CcSEcCtD
Ponatinib—Oedema—Saquinavir—acquired immunodeficiency syndrome	0.000119	0.000564	CcSEcCtD
Ponatinib—ABCB1—blood—acquired immunodeficiency syndrome	0.000119	0.00119	CbGeAlD
Ponatinib—Headache—Nevirapine—acquired immunodeficiency syndrome	0.000119	0.000562	CcSEcCtD
Ponatinib—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	0.000119	0.000561	CcSEcCtD
Ponatinib—Myalgia—Lamivudine—acquired immunodeficiency syndrome	0.000119	0.000561	CcSEcCtD
Ponatinib—Infection—Saquinavir—acquired immunodeficiency syndrome	0.000119	0.00056	CcSEcCtD
Ponatinib—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	0.000118	0.000558	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	0.000118	0.000557	CcSEcCtD
Ponatinib—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	0.000117	0.000554	CcSEcCtD
Ponatinib—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	0.000117	0.000554	CcSEcCtD
Ponatinib—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	0.000117	0.000553	CcSEcCtD
Ponatinib—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	0.000117	0.000553	CcSEcCtD
Ponatinib—Thrombocytopenia—Saquinavir—acquired immunodeficiency syndrome	0.000117	0.000552	CcSEcCtD
Ponatinib—Vomiting—Stavudine—acquired immunodeficiency syndrome	0.000117	0.000551	CcSEcCtD
Ponatinib—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	0.000117	0.000551	CcSEcCtD
Ponatinib—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	0.000116	0.000549	CcSEcCtD
Ponatinib—Rash—Nelfinavir—acquired immunodeficiency syndrome	0.000116	0.000548	CcSEcCtD
Ponatinib—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	0.000116	0.000548	CcSEcCtD
Ponatinib—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	0.000116	0.000548	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	0.000116	0.000547	CcSEcCtD
Ponatinib—Rash—Stavudine—acquired immunodeficiency syndrome	0.000116	0.000547	CcSEcCtD
Ponatinib—Fatigue—Delavirdine—acquired immunodeficiency syndrome	0.000116	0.000546	CcSEcCtD
Ponatinib—Dermatitis—Stavudine—acquired immunodeficiency syndrome	0.000116	0.000546	CcSEcCtD
Ponatinib—ABCB1—bone marrow—acquired immunodeficiency syndrome	0.000116	0.00116	CbGeAlD
Ponatinib—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	0.000115	0.000545	CcSEcCtD
Ponatinib—Headache—Nelfinavir—acquired immunodeficiency syndrome	0.000115	0.000545	CcSEcCtD
Ponatinib—ABCB1—spinal cord—acquired immunodeficiency syndrome	0.000115	0.00115	CbGeAlD
Ponatinib—Headache—Stavudine—acquired immunodeficiency syndrome	0.000115	0.000543	CcSEcCtD
Ponatinib—Vomiting—Abacavir—acquired immunodeficiency syndrome	0.000115	0.000543	CcSEcCtD
Ponatinib—Constipation—Delavirdine—acquired immunodeficiency syndrome	0.000115	0.000542	CcSEcCtD
Ponatinib—Pain—Delavirdine—acquired immunodeficiency syndrome	0.000115	0.000542	CcSEcCtD
Ponatinib—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	0.000115	0.000541	CcSEcCtD
Ponatinib—Asthenia—Zidovudine—acquired immunodeficiency syndrome	0.000114	0.000541	CcSEcCtD
Ponatinib—Rash—Abacavir—acquired immunodeficiency syndrome	0.000114	0.000538	CcSEcCtD
Ponatinib—Dermatitis—Abacavir—acquired immunodeficiency syndrome	0.000114	0.000538	CcSEcCtD
Ponatinib—Oedema—Lamivudine—acquired immunodeficiency syndrome	0.000114	0.000538	CcSEcCtD
Ponatinib—Headache—Abacavir—acquired immunodeficiency syndrome	0.000113	0.000535	CcSEcCtD
Ponatinib—Infection—Lamivudine—acquired immunodeficiency syndrome	0.000113	0.000534	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	0.000113	0.000534	CcSEcCtD
Ponatinib—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.000113	0.000533	CcSEcCtD
Ponatinib—Pruritus—Zidovudine—acquired immunodeficiency syndrome	0.000113	0.000533	CcSEcCtD
Ponatinib—Insomnia—Ritonavir—acquired immunodeficiency syndrome	0.000112	0.00053	CcSEcCtD
Ponatinib—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	0.000112	0.000527	CcSEcCtD
Ponatinib—Thrombocytopenia—Lamivudine—acquired immunodeficiency syndrome	0.000112	0.000527	CcSEcCtD
Ponatinib—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	0.000111	0.000526	CcSEcCtD
Ponatinib—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	0.000111	0.000523	CcSEcCtD
Ponatinib—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	0.000111	0.000523	CcSEcCtD
Ponatinib—ABCB1—vagina—acquired immunodeficiency syndrome	0.000111	0.00111	CbGeAlD
Ponatinib—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	0.000111	0.000522	CcSEcCtD
Ponatinib—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	0.000111	0.000522	CcSEcCtD
Ponatinib—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	0.00011	0.00052	CcSEcCtD
Ponatinib—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	0.00011	0.000518	CcSEcCtD
Ponatinib—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.000109	0.000517	CcSEcCtD
Ponatinib—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	0.000109	0.000516	CcSEcCtD
Ponatinib—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	0.000109	0.000516	CcSEcCtD
Ponatinib—Nausea—Stavudine—acquired immunodeficiency syndrome	0.000109	0.000515	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	0.000109	0.000514	CcSEcCtD
Ponatinib—Insomnia—Saquinavir—acquired immunodeficiency syndrome	0.000108	0.00051	CcSEcCtD
Ponatinib—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	0.000108	0.000509	CcSEcCtD
Ponatinib—Nausea—Abacavir—acquired immunodeficiency syndrome	0.000107	0.000507	CcSEcCtD
Ponatinib—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	0.000107	0.000506	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	0.000107	0.000506	CcSEcCtD
Ponatinib—Fatigue—Ritonavir—acquired immunodeficiency syndrome	0.000107	0.000505	CcSEcCtD
Ponatinib—Asthenia—Indinavir—acquired immunodeficiency syndrome	0.000106	0.000503	CcSEcCtD
Ponatinib—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	0.000106	0.000503	CcSEcCtD
Ponatinib—Pain—Ritonavir—acquired immunodeficiency syndrome	0.000106	0.000501	CcSEcCtD
Ponatinib—Constipation—Ritonavir—acquired immunodeficiency syndrome	0.000106	0.000501	CcSEcCtD
Ponatinib—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	0.000106	0.000501	CcSEcCtD
Ponatinib—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	0.000106	0.000501	CcSEcCtD
Ponatinib—Dizziness—Zidovudine—acquired immunodeficiency syndrome	0.000106	0.000498	CcSEcCtD
Ponatinib—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	0.000105	0.000496	CcSEcCtD
Ponatinib—Pruritus—Indinavir—acquired immunodeficiency syndrome	0.000105	0.000496	CcSEcCtD
Ponatinib—ABCB1—lung—acquired immunodeficiency syndrome	0.000105	0.00105	CbGeAlD
Ponatinib—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	0.000104	0.00049	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	0.000104	0.00049	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	0.000103	0.000487	CcSEcCtD
Ponatinib—Insomnia—Lamivudine—acquired immunodeficiency syndrome	0.000103	0.000486	CcSEcCtD
Ponatinib—CYP2D6—brain—acquired immunodeficiency syndrome	0.000103	0.00103	CbGeAlD
Ponatinib—Fatigue—Saquinavir—acquired immunodeficiency syndrome	0.000103	0.000486	CcSEcCtD
Ponatinib—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	0.000102	0.000483	CcSEcCtD
Ponatinib—Pain—Saquinavir—acquired immunodeficiency syndrome	0.000102	0.000482	CcSEcCtD
Ponatinib—Constipation—Saquinavir—acquired immunodeficiency syndrome	0.000102	0.000482	CcSEcCtD
Ponatinib—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	0.000102	0.00048	CcSEcCtD
Ponatinib—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	0.000102	0.000479	CcSEcCtD
Ponatinib—Vomiting—Zidovudine—acquired immunodeficiency syndrome	0.000101	0.000479	CcSEcCtD
Ponatinib—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	0.000101	0.000479	CcSEcCtD
Ponatinib—Rash—Zidovudine—acquired immunodeficiency syndrome	0.000101	0.000475	CcSEcCtD
Ponatinib—Asthenia—Efavirenz—acquired immunodeficiency syndrome	0.000101	0.000475	CcSEcCtD
Ponatinib—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	0.000101	0.000475	CcSEcCtD
Ponatinib—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	0.0001	0.000473	CcSEcCtD
Ponatinib—Headache—Zidovudine—acquired immunodeficiency syndrome	0.0001	0.000472	CcSEcCtD
Ponatinib—Pruritus—Efavirenz—acquired immunodeficiency syndrome	9.92e-05	0.000468	CcSEcCtD
Ponatinib—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	9.9e-05	0.000468	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	9.84e-05	0.000464	CcSEcCtD
Ponatinib—Fatigue—Lamivudine—acquired immunodeficiency syndrome	9.82e-05	0.000464	CcSEcCtD
Ponatinib—Dizziness—Indinavir—acquired immunodeficiency syndrome	9.81e-05	0.000463	CcSEcCtD
Ponatinib—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	9.81e-05	0.000463	CcSEcCtD
Ponatinib—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	9.81e-05	0.000463	CcSEcCtD
Ponatinib—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	9.76e-05	0.000461	CcSEcCtD
Ponatinib—Pain—Lamivudine—acquired immunodeficiency syndrome	9.74e-05	0.00046	CcSEcCtD
Ponatinib—Constipation—Lamivudine—acquired immunodeficiency syndrome	9.74e-05	0.00046	CcSEcCtD
Ponatinib—ABCB1—nervous system—acquired immunodeficiency syndrome	9.69e-05	0.000969	CbGeAlD
Ponatinib—Asthenia—Delavirdine—acquired immunodeficiency syndrome	9.63e-05	0.000454	CcSEcCtD
Ponatinib—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	9.59e-05	0.000453	CcSEcCtD
Ponatinib—Pruritus—Delavirdine—acquired immunodeficiency syndrome	9.49e-05	0.000448	CcSEcCtD
Ponatinib—Nausea—Zidovudine—acquired immunodeficiency syndrome	9.48e-05	0.000448	CcSEcCtD
Ponatinib—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	9.44e-05	0.000446	CcSEcCtD
Ponatinib—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	9.44e-05	0.000446	CcSEcCtD
Ponatinib—Vomiting—Indinavir—acquired immunodeficiency syndrome	9.44e-05	0.000446	CcSEcCtD
Ponatinib—Rash—Indinavir—acquired immunodeficiency syndrome	9.36e-05	0.000442	CcSEcCtD
Ponatinib—Dermatitis—Indinavir—acquired immunodeficiency syndrome	9.35e-05	0.000441	CcSEcCtD
Ponatinib—ABCB1—central nervous system—acquired immunodeficiency syndrome	9.33e-05	0.000933	CbGeAlD
Ponatinib—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	9.32e-05	0.00044	CcSEcCtD
Ponatinib—Headache—Indinavir—acquired immunodeficiency syndrome	9.3e-05	0.000439	CcSEcCtD
Ponatinib—Dizziness—Efavirenz—acquired immunodeficiency syndrome	9.27e-05	0.000438	CcSEcCtD
Ponatinib—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	9.18e-05	0.000433	CcSEcCtD
Ponatinib—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	9.01e-05	0.000425	CcSEcCtD
Ponatinib—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	9.01e-05	0.000425	CcSEcCtD
Ponatinib—Vomiting—Efavirenz—acquired immunodeficiency syndrome	8.92e-05	0.000421	CcSEcCtD
Ponatinib—Asthenia—Ritonavir—acquired immunodeficiency syndrome	8.9e-05	0.00042	CcSEcCtD
Ponatinib—Dizziness—Delavirdine—acquired immunodeficiency syndrome	8.87e-05	0.000419	CcSEcCtD
Ponatinib—Rash—Efavirenz—acquired immunodeficiency syndrome	8.84e-05	0.000417	CcSEcCtD
Ponatinib—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	8.83e-05	0.000417	CcSEcCtD
Ponatinib—Nausea—Indinavir—acquired immunodeficiency syndrome	8.82e-05	0.000416	CcSEcCtD
Ponatinib—Headache—Efavirenz—acquired immunodeficiency syndrome	8.78e-05	0.000415	CcSEcCtD
Ponatinib—Pruritus—Ritonavir—acquired immunodeficiency syndrome	8.78e-05	0.000414	CcSEcCtD
Ponatinib—Asthenia—Saquinavir—acquired immunodeficiency syndrome	8.57e-05	0.000405	CcSEcCtD
Ponatinib—Vomiting—Delavirdine—acquired immunodeficiency syndrome	8.53e-05	0.000403	CcSEcCtD
Ponatinib—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	8.49e-05	0.000401	CcSEcCtD
Ponatinib—Rash—Delavirdine—acquired immunodeficiency syndrome	8.46e-05	0.000399	CcSEcCtD
Ponatinib—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	8.45e-05	0.000399	CcSEcCtD
Ponatinib—Pruritus—Saquinavir—acquired immunodeficiency syndrome	8.45e-05	0.000399	CcSEcCtD
Ponatinib—Headache—Delavirdine—acquired immunodeficiency syndrome	8.4e-05	0.000397	CcSEcCtD
Ponatinib—Nausea—Efavirenz—acquired immunodeficiency syndrome	8.33e-05	0.000393	CcSEcCtD
Ponatinib—Dizziness—Ritonavir—acquired immunodeficiency syndrome	8.2e-05	0.000387	CcSEcCtD
Ponatinib—Asthenia—Lamivudine—acquired immunodeficiency syndrome	8.17e-05	0.000386	CcSEcCtD
Ponatinib—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	8.17e-05	0.000386	CcSEcCtD
Ponatinib—Pruritus—Lamivudine—acquired immunodeficiency syndrome	8.06e-05	0.000381	CcSEcCtD
Ponatinib—Nausea—Delavirdine—acquired immunodeficiency syndrome	7.97e-05	0.000376	CcSEcCtD
Ponatinib—Dizziness—Saquinavir—acquired immunodeficiency syndrome	7.9e-05	0.000373	CcSEcCtD
Ponatinib—Vomiting—Ritonavir—acquired immunodeficiency syndrome	7.89e-05	0.000372	CcSEcCtD
Ponatinib—Rash—Ritonavir—acquired immunodeficiency syndrome	7.82e-05	0.000369	CcSEcCtD
Ponatinib—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	7.82e-05	0.000369	CcSEcCtD
Ponatinib—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	7.79e-05	0.000368	CcSEcCtD
Ponatinib—Headache—Ritonavir—acquired immunodeficiency syndrome	7.77e-05	0.000367	CcSEcCtD
Ponatinib—Vomiting—Saquinavir—acquired immunodeficiency syndrome	7.59e-05	0.000358	CcSEcCtD
Ponatinib—Dizziness—Lamivudine—acquired immunodeficiency syndrome	7.53e-05	0.000356	CcSEcCtD
Ponatinib—Rash—Saquinavir—acquired immunodeficiency syndrome	7.53e-05	0.000356	CcSEcCtD
Ponatinib—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	7.52e-05	0.000355	CcSEcCtD
Ponatinib—Headache—Saquinavir—acquired immunodeficiency syndrome	7.48e-05	0.000353	CcSEcCtD
Ponatinib—ABCB1—brain—acquired immunodeficiency syndrome	7.41e-05	0.000741	CbGeAlD
Ponatinib—Nausea—Ritonavir—acquired immunodeficiency syndrome	7.37e-05	0.000348	CcSEcCtD
Ponatinib—Vomiting—Lamivudine—acquired immunodeficiency syndrome	7.24e-05	0.000342	CcSEcCtD
Ponatinib—Rash—Lamivudine—acquired immunodeficiency syndrome	7.18e-05	0.000339	CcSEcCtD
Ponatinib—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	7.18e-05	0.000339	CcSEcCtD
Ponatinib—ABCB1—lymph node—acquired immunodeficiency syndrome	7.16e-05	0.000716	CbGeAlD
Ponatinib—Headache—Lamivudine—acquired immunodeficiency syndrome	7.14e-05	0.000337	CcSEcCtD
Ponatinib—Nausea—Saquinavir—acquired immunodeficiency syndrome	7.09e-05	0.000335	CcSEcCtD
Ponatinib—Nausea—Lamivudine—acquired immunodeficiency syndrome	6.77e-05	0.000319	CcSEcCtD
Ponatinib—FGFR3—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.48e-05	0.000368	CbGpPWpGaD
Ponatinib—LCK—Immune System—CCR2—acquired immunodeficiency syndrome	2.48e-05	0.000368	CbGpPWpGaD
Ponatinib—BCR—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.48e-05	0.000368	CbGpPWpGaD
Ponatinib—SRC—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	2.48e-05	0.000367	CbGpPWpGaD
Ponatinib—KDR—Developmental Biology—TNF—acquired immunodeficiency syndrome	2.47e-05	0.000366	CbGpPWpGaD
Ponatinib—FGFR2—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	2.47e-05	0.000365	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.46e-05	0.000365	CbGpPWpGaD
Ponatinib—KIT—Immune System—HLA-B—acquired immunodeficiency syndrome	2.46e-05	0.000364	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—HLA-B—acquired immunodeficiency syndrome	2.46e-05	0.000364	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.46e-05	0.000364	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—CD40LG—acquired immunodeficiency syndrome	2.45e-05	0.000364	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—CD40LG—acquired immunodeficiency syndrome	2.45e-05	0.000363	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.45e-05	0.000363	CbGpPWpGaD
Ponatinib—FGFR2—Signaling by NGF—IL6—acquired immunodeficiency syndrome	2.43e-05	0.000361	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—CD8A—acquired immunodeficiency syndrome	2.43e-05	0.00036	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—CSF2—acquired immunodeficiency syndrome	2.43e-05	0.00036	CbGpPWpGaD
Ponatinib—KIT—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	2.42e-05	0.000359	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—CD8A—acquired immunodeficiency syndrome	2.42e-05	0.000359	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—CSF2—acquired immunodeficiency syndrome	2.42e-05	0.000359	CbGpPWpGaD
Ponatinib—LCK—Fc epsilon receptor (FCERI) signaling—IL6—acquired immunodeficiency syndrome	2.4e-05	0.000356	CbGpPWpGaD
Ponatinib—LCK—Signaling by FGFR in disease—IL6—acquired immunodeficiency syndrome	2.4e-05	0.000356	CbGpPWpGaD
Ponatinib—LCK—DAP12 interactions—IL6—acquired immunodeficiency syndrome	2.4e-05	0.000356	CbGpPWpGaD
Ponatinib—FGFR1—Innate Immune System—CD4—acquired immunodeficiency syndrome	2.39e-05	0.000355	CbGpPWpGaD
Ponatinib—KIT—Signaling by NGF—IL6—acquired immunodeficiency syndrome	2.39e-05	0.000354	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.39e-05	0.000354	CbGpPWpGaD
Ponatinib—PDGFRA—Innate Immune System—CD4—acquired immunodeficiency syndrome	2.39e-05	0.000354	CbGpPWpGaD
Ponatinib—LCK—Signaling by EGFR—IL6—acquired immunodeficiency syndrome	2.38e-05	0.000353	CbGpPWpGaD
Ponatinib—LCK—Signaling by EGFR in Cancer—IL6—acquired immunodeficiency syndrome	2.36e-05	0.00035	CbGpPWpGaD
Ponatinib—LCK—Signaling by PDGF—IL6—acquired immunodeficiency syndrome	2.35e-05	0.000348	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.35e-05	0.000348	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—HLA-B—acquired immunodeficiency syndrome	2.33e-05	0.000346	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—HLA-B—acquired immunodeficiency syndrome	2.33e-05	0.000345	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	2.3e-05	0.000341	CbGpPWpGaD
Ponatinib—FGFR1—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	2.3e-05	0.00034	CbGpPWpGaD
Ponatinib—SRC—Downstream signal transduction—IL6—acquired immunodeficiency syndrome	2.29e-05	0.00034	CbGpPWpGaD
Ponatinib—PDGFRA—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	2.29e-05	0.00034	CbGpPWpGaD
Ponatinib—SRC—Signaling by FGFR—IL6—acquired immunodeficiency syndrome	2.28e-05	0.000338	CbGpPWpGaD
Ponatinib—SRC—Signaling by ERBB2—IL6—acquired immunodeficiency syndrome	2.27e-05	0.000337	CbGpPWpGaD
Ponatinib—FGFR1—Signaling by NGF—IL6—acquired immunodeficiency syndrome	2.27e-05	0.000336	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling by NGF—IL6—acquired immunodeficiency syndrome	2.26e-05	0.000335	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—AGPS—acquired immunodeficiency syndrome	2.25e-05	0.000334	CbGpPWpGaD
Ponatinib—FGFR3—Immune System—IFNG—acquired immunodeficiency syndrome	2.25e-05	0.000334	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.25e-05	0.000333	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.25e-05	0.000333	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.24e-05	0.000332	CbGpPWpGaD
Ponatinib—LCK—Immune System—IFNA1—acquired immunodeficiency syndrome	2.24e-05	0.000331	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.23e-05	0.00033	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.22e-05	0.000329	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.21e-05	0.000327	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.21e-05	0.000327	CbGpPWpGaD
Ponatinib—SRC—Immune System—CCR2—acquired immunodeficiency syndrome	2.2e-05	0.000326	CbGpPWpGaD
Ponatinib—FGFR2—Disease—CCR5—acquired immunodeficiency syndrome	2.2e-05	0.000326	CbGpPWpGaD
Ponatinib—LCK—Hemostasis—ALB—acquired immunodeficiency syndrome	2.17e-05	0.000322	CbGpPWpGaD
Ponatinib—FGFR3—Immune System—CD4—acquired immunodeficiency syndrome	2.17e-05	0.000322	CbGpPWpGaD
Ponatinib—LCK—Immune System—CD79A—acquired immunodeficiency syndrome	2.17e-05	0.000322	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.17e-05	0.000321	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.16e-05	0.000321	CbGpPWpGaD
Ponatinib—KIT—Disease—CCR5—acquired immunodeficiency syndrome	2.16e-05	0.00032	CbGpPWpGaD
Ponatinib—LYN—Immune System—CD40LG—acquired immunodeficiency syndrome	2.16e-05	0.00032	CbGpPWpGaD
Ponatinib—LCK—Disease—CXCR4—acquired immunodeficiency syndrome	2.16e-05	0.000319	CbGpPWpGaD
Ponatinib—LYN—Hemostasis—IL2—acquired immunodeficiency syndrome	2.15e-05	0.000319	CbGpPWpGaD
Ponatinib—ABL1—Immune System—CD40LG—acquired immunodeficiency syndrome	2.15e-05	0.000318	CbGpPWpGaD
Ponatinib—ABL1—Hemostasis—IL2—acquired immunodeficiency syndrome	2.14e-05	0.000317	CbGpPWpGaD
Ponatinib—LYN—Immune System—CSF2—acquired immunodeficiency syndrome	2.13e-05	0.000316	CbGpPWpGaD
Ponatinib—LYN—Immune System—CD8A—acquired immunodeficiency syndrome	2.13e-05	0.000316	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.13e-05	0.000316	CbGpPWpGaD
Ponatinib—LCK—NGF signalling via TRKA from the plasma membrane—IL6—acquired immunodeficiency syndrome	2.13e-05	0.000315	CbGpPWpGaD
Ponatinib—SRC—Signaling by FGFR in disease—IL6—acquired immunodeficiency syndrome	2.13e-05	0.000315	CbGpPWpGaD
Ponatinib—ABL1—Immune System—CD8A—acquired immunodeficiency syndrome	2.12e-05	0.000315	CbGpPWpGaD
Ponatinib—ABL1—Immune System—CSF2—acquired immunodeficiency syndrome	2.12e-05	0.000315	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—AGPS—acquired immunodeficiency syndrome	2.12e-05	0.000314	CbGpPWpGaD
Ponatinib—SRC—Signaling by EGFR—IL6—acquired immunodeficiency syndrome	2.11e-05	0.000312	CbGpPWpGaD
Ponatinib—LYN—Innate Immune System—CD4—acquired immunodeficiency syndrome	2.11e-05	0.000312	CbGpPWpGaD
Ponatinib—ABL1—Innate Immune System—CD4—acquired immunodeficiency syndrome	2.1e-05	0.00031	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.09e-05	0.00031	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.09e-05	0.00031	CbGpPWpGaD
Ponatinib—SRC—Signaling by EGFR in Cancer—IL6—acquired immunodeficiency syndrome	2.09e-05	0.000309	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.09e-05	0.000309	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.09e-05	0.000309	CbGpPWpGaD
Ponatinib—BCR—Disease—IL6—acquired immunodeficiency syndrome	2.08e-05	0.000309	CbGpPWpGaD
Ponatinib—SRC—Signaling by PDGF—IL6—acquired immunodeficiency syndrome	2.08e-05	0.000308	CbGpPWpGaD
Ponatinib—LYN—Immune System—HLA-B—acquired immunodeficiency syndrome	2.05e-05	0.000304	CbGpPWpGaD
Ponatinib—FGFR1—Axon guidance—IL6—acquired immunodeficiency syndrome	2.05e-05	0.000304	CbGpPWpGaD
Ponatinib—FGFR1—Disease—CCR5—acquired immunodeficiency syndrome	2.05e-05	0.000304	CbGpPWpGaD
Ponatinib—ABL1—Immune System—HLA-B—acquired immunodeficiency syndrome	2.04e-05	0.000303	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—CCR5—acquired immunodeficiency syndrome	2.04e-05	0.000303	CbGpPWpGaD
Ponatinib—LYN—Cytokine Signaling in Immune system—IL6—acquired immunodeficiency syndrome	2.03e-05	0.000301	CbGpPWpGaD
Ponatinib—LYN—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	2.02e-05	0.0003	CbGpPWpGaD
Ponatinib—FGFR3—Innate Immune System—IL6—acquired immunodeficiency syndrome	2.02e-05	0.000299	CbGpPWpGaD
Ponatinib—FGFR3—Disease—CD4—acquired immunodeficiency syndrome	2.01e-05	0.000297	CbGpPWpGaD
Ponatinib—FGFR3—Immune System—IL2—acquired immunodeficiency syndrome	2e-05	0.000296	CbGpPWpGaD
Ponatinib—KDR—Developmental Biology—IL6—acquired immunodeficiency syndrome	1.99e-05	0.000295	CbGpPWpGaD
Ponatinib—SRC—Immune System—IFNA1—acquired immunodeficiency syndrome	1.98e-05	0.000293	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.96e-05	0.00029	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.95e-05	0.000289	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—ALB—acquired immunodeficiency syndrome	1.93e-05	0.000285	CbGpPWpGaD
Ponatinib—SRC—Immune System—CD79A—acquired immunodeficiency syndrome	1.92e-05	0.000285	CbGpPWpGaD
Ponatinib—SRC—Disease—CXCR4—acquired immunodeficiency syndrome	1.91e-05	0.000283	CbGpPWpGaD
Ponatinib—SRC—NGF signalling via TRKA from the plasma membrane—IL6—acquired immunodeficiency syndrome	1.88e-05	0.000279	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.84e-05	0.000273	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.84e-05	0.000273	CbGpPWpGaD
Ponatinib—ABCG2—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	1.82e-05	0.00027	CbGpPWpGaD
Ponatinib—FGFR1—Developmental Biology—TNF—acquired immunodeficiency syndrome	1.82e-05	0.000269	CbGpPWpGaD
Ponatinib—LYN—Axon guidance—IL6—acquired immunodeficiency syndrome	1.81e-05	0.000268	CbGpPWpGaD
Ponatinib—ABL1—Axon guidance—IL6—acquired immunodeficiency syndrome	1.8e-05	0.000266	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.78e-05	0.000263	CbGpPWpGaD
Ponatinib—LCK—Immune System—CD40LG—acquired immunodeficiency syndrome	1.77e-05	0.000262	CbGpPWpGaD
Ponatinib—LCK—Hemostasis—IL2—acquired immunodeficiency syndrome	1.76e-05	0.000261	CbGpPWpGaD
Ponatinib—LCK—Immune System—CSF2—acquired immunodeficiency syndrome	1.75e-05	0.000259	CbGpPWpGaD
Ponatinib—LCK—Immune System—CD8A—acquired immunodeficiency syndrome	1.75e-05	0.000259	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.75e-05	0.000259	CbGpPWpGaD
Ponatinib—LCK—Innate Immune System—CD4—acquired immunodeficiency syndrome	1.73e-05	0.000256	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.71e-05	0.000253	CbGpPWpGaD
Ponatinib—LCK—Immune System—HLA-B—acquired immunodeficiency syndrome	1.68e-05	0.000249	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.68e-05	0.000249	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.68e-05	0.000249	CbGpPWpGaD
Ponatinib—LCK—Cytokine Signaling in Immune system—IL6—acquired immunodeficiency syndrome	1.66e-05	0.000247	CbGpPWpGaD
Ponatinib—LCK—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	1.66e-05	0.000246	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.65e-05	0.000245	CbGpPWpGaD
Ponatinib—LCK—Signaling by NGF—IL6—acquired immunodeficiency syndrome	1.64e-05	0.000242	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—TAT—acquired immunodeficiency syndrome	1.63e-05	0.000242	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.61e-05	0.000238	CbGpPWpGaD
Ponatinib—LYN—Developmental Biology—TNF—acquired immunodeficiency syndrome	1.6e-05	0.000237	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.59e-05	0.000236	CbGpPWpGaD
Ponatinib—ABL1—Developmental Biology—TNF—acquired immunodeficiency syndrome	1.59e-05	0.000236	CbGpPWpGaD
Ponatinib—FGFR4—Immune System—IL6—acquired immunodeficiency syndrome	1.59e-05	0.000236	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.59e-05	0.000235	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.57e-05	0.000233	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.57e-05	0.000232	CbGpPWpGaD
Ponatinib—SRC—Immune System—CD40LG—acquired immunodeficiency syndrome	1.57e-05	0.000232	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.56e-05	0.000232	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—IL2—acquired immunodeficiency syndrome	1.56e-05	0.000231	CbGpPWpGaD
Ponatinib—SRC—Immune System—CSF2—acquired immunodeficiency syndrome	1.55e-05	0.00023	CbGpPWpGaD
Ponatinib—SRC—Immune System—CD8A—acquired immunodeficiency syndrome	1.55e-05	0.00023	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—IFNG—acquired immunodeficiency syndrome	1.55e-05	0.000229	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.54e-05	0.000228	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—CD4—acquired immunodeficiency syndrome	1.53e-05	0.000226	CbGpPWpGaD
Ponatinib—KIT—Immune System—IFNG—acquired immunodeficiency syndrome	1.52e-05	0.000225	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.51e-05	0.000224	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.51e-05	0.000224	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.51e-05	0.000224	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—CD4—acquired immunodeficiency syndrome	1.5e-05	0.000222	CbGpPWpGaD
Ponatinib—SRC—Immune System—HLA-B—acquired immunodeficiency syndrome	1.49e-05	0.000221	CbGpPWpGaD
Ponatinib—LCK—Disease—CCR5—acquired immunodeficiency syndrome	1.48e-05	0.000219	CbGpPWpGaD
Ponatinib—KIT—Immune System—CD4—acquired immunodeficiency syndrome	1.47e-05	0.000218	CbGpPWpGaD
Ponatinib—FGFR4—Disease—IL6—acquired immunodeficiency syndrome	1.47e-05	0.000217	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	1.47e-05	0.000217	CbGpPWpGaD
Ponatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	1.47e-05	0.000217	CbGpPWpGaD
Ponatinib—FGFR1—Developmental Biology—IL6—acquired immunodeficiency syndrome	1.47e-05	0.000217	CbGpPWpGaD
Ponatinib—BCR—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.46e-05	0.000216	CbGpPWpGaD
Ponatinib—SRC—Signaling by NGF—IL6—acquired immunodeficiency syndrome	1.45e-05	0.000215	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—IFNG—acquired immunodeficiency syndrome	1.44e-05	0.000214	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—IFNG—acquired immunodeficiency syndrome	1.44e-05	0.000213	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.43e-05	0.000213	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.43e-05	0.000212	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.42e-05	0.000211	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.4e-05	0.000208	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—CD4—acquired immunodeficiency syndrome	1.39e-05	0.000207	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—CD4—acquired immunodeficiency syndrome	1.39e-05	0.000206	CbGpPWpGaD
Ponatinib—FGFR2—Innate Immune System—IL6—acquired immunodeficiency syndrome	1.39e-05	0.000206	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	1.39e-05	0.000206	CbGpPWpGaD
Ponatinib—FGFR2—Disease—CD4—acquired immunodeficiency syndrome	1.38e-05	0.000205	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.38e-05	0.000205	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—IL2—acquired immunodeficiency syndrome	1.38e-05	0.000204	CbGpPWpGaD
Ponatinib—KIT—Innate Immune System—IL6—acquired immunodeficiency syndrome	1.36e-05	0.000202	CbGpPWpGaD
Ponatinib—KIT—Disease—CD4—acquired immunodeficiency syndrome	1.36e-05	0.000201	CbGpPWpGaD
Ponatinib—KIT—Immune System—IL2—acquired immunodeficiency syndrome	1.35e-05	0.0002	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.34e-05	0.000198	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.34e-05	0.000198	CbGpPWpGaD
Ponatinib—SRC—Axon guidance—IL6—acquired immunodeficiency syndrome	1.31e-05	0.000194	CbGpPWpGaD
Ponatinib—SRC—Disease—CCR5—acquired immunodeficiency syndrome	1.31e-05	0.000194	CbGpPWpGaD
Ponatinib—FGFR1—Innate Immune System—IL6—acquired immunodeficiency syndrome	1.29e-05	0.000192	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.29e-05	0.000192	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—ALB—acquired immunodeficiency syndrome	1.29e-05	0.000191	CbGpPWpGaD
Ponatinib—PDGFRA—Innate Immune System—IL6—acquired immunodeficiency syndrome	1.29e-05	0.000191	CbGpPWpGaD
Ponatinib—LYN—Developmental Biology—IL6—acquired immunodeficiency syndrome	1.29e-05	0.000191	CbGpPWpGaD
Ponatinib—FGFR1—Disease—CD4—acquired immunodeficiency syndrome	1.29e-05	0.000191	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—CD4—acquired immunodeficiency syndrome	1.28e-05	0.00019	CbGpPWpGaD
Ponatinib—ABL1—Developmental Biology—IL6—acquired immunodeficiency syndrome	1.28e-05	0.00019	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—IL2—acquired immunodeficiency syndrome	1.28e-05	0.00019	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—IL2—acquired immunodeficiency syndrome	1.28e-05	0.00019	CbGpPWpGaD
Ponatinib—LYN—Immune System—IFNG—acquired immunodeficiency syndrome	1.27e-05	0.000188	CbGpPWpGaD
Ponatinib—ABL1—Immune System—IFNG—acquired immunodeficiency syndrome	1.26e-05	0.000187	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.26e-05	0.000187	CbGpPWpGaD
Ponatinib—LYN—Immune System—CD4—acquired immunodeficiency syndrome	1.23e-05	0.000182	CbGpPWpGaD
Ponatinib—ABL1—Immune System—CD4—acquired immunodeficiency syndrome	1.22e-05	0.000181	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	1.19e-05	0.000176	CbGpPWpGaD
Ponatinib—FGFR3—Immune System—IL6—acquired immunodeficiency syndrome	1.18e-05	0.000174	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—TNF—acquired immunodeficiency syndrome	1.16e-05	0.000172	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.15e-05	0.00017	CbGpPWpGaD
Ponatinib—LYN—Innate Immune System—IL6—acquired immunodeficiency syndrome	1.14e-05	0.000169	CbGpPWpGaD
Ponatinib—ABL1—Innate Immune System—IL6—acquired immunodeficiency syndrome	1.13e-05	0.000168	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.13e-05	0.000168	CbGpPWpGaD
Ponatinib—LYN—Immune System—IL2—acquired immunodeficiency syndrome	1.13e-05	0.000167	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.13e-05	0.000167	CbGpPWpGaD
Ponatinib—ABL1—Immune System—IL2—acquired immunodeficiency syndrome	1.12e-05	0.000166	CbGpPWpGaD
Ponatinib—FGFR3—Disease—IL6—acquired immunodeficiency syndrome	1.09e-05	0.000161	CbGpPWpGaD
Ponatinib—LCK—Immune System—IFNG—acquired immunodeficiency syndrome	1.04e-05	0.000154	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.03e-05	0.000153	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.03e-05	0.000152	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.02e-05	0.000151	CbGpPWpGaD
Ponatinib—LCK—Immune System—CD4—acquired immunodeficiency syndrome	1.01e-05	0.000149	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1e-05	0.000148	CbGpPWpGaD
Ponatinib—ABCB1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	9.86e-06	0.000146	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—IL6—acquired immunodeficiency syndrome	9.35e-06	0.000139	CbGpPWpGaD
Ponatinib—LCK—Innate Immune System—IL6—acquired immunodeficiency syndrome	9.33e-06	0.000138	CbGpPWpGaD
Ponatinib—LCK—Disease—CD4—acquired immunodeficiency syndrome	9.28e-06	0.000137	CbGpPWpGaD
Ponatinib—LCK—Immune System—IL2—acquired immunodeficiency syndrome	9.25e-06	0.000137	CbGpPWpGaD
Ponatinib—SRC—Immune System—IFNG—acquired immunodeficiency syndrome	9.21e-06	0.000137	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	9.16e-06	0.000136	CbGpPWpGaD
Ponatinib—SRC—Immune System—CD4—acquired immunodeficiency syndrome	8.9e-06	0.000132	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	8.89e-06	0.000132	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—IL2—acquired immunodeficiency syndrome	8.74e-06	0.000129	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—ALB—acquired immunodeficiency syndrome	8.54e-06	0.000127	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	8.29e-06	0.000123	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—IL2—acquired immunodeficiency syndrome	8.27e-06	0.000123	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—IL6—acquired immunodeficiency syndrome	8.26e-06	0.000122	CbGpPWpGaD
Ponatinib—SRC—Disease—CD4—acquired immunodeficiency syndrome	8.21e-06	0.000122	CbGpPWpGaD
Ponatinib—SRC—Immune System—IL2—acquired immunodeficiency syndrome	8.19e-06	0.000121	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—IL6—acquired immunodeficiency syndrome	8.09e-06	0.00012	CbGpPWpGaD
Ponatinib—KIT—Immune System—IL6—acquired immunodeficiency syndrome	7.94e-06	0.000118	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—IL6—acquired immunodeficiency syndrome	7.6e-06	0.000113	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—IL6—acquired immunodeficiency syndrome	7.54e-06	0.000112	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—IL6—acquired immunodeficiency syndrome	7.52e-06	0.000111	CbGpPWpGaD
Ponatinib—FGFR2—Disease—IL6—acquired immunodeficiency syndrome	7.47e-06	0.000111	CbGpPWpGaD
Ponatinib—KIT—Disease—IL6—acquired immunodeficiency syndrome	7.33e-06	0.000109	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—IL2—acquired immunodeficiency syndrome	7.29e-06	0.000108	CbGpPWpGaD
Ponatinib—FGFR1—Disease—IL6—acquired immunodeficiency syndrome	6.96e-06	0.000103	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—IL6—acquired immunodeficiency syndrome	6.94e-06	0.000103	CbGpPWpGaD
Ponatinib—LYN—Immune System—IL6—acquired immunodeficiency syndrome	6.63e-06	9.83e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—IL6—acquired immunodeficiency syndrome	6.62e-06	9.81e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—IL6—acquired immunodeficiency syndrome	6.6e-06	9.78e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—ALB—acquired immunodeficiency syndrome	6.12e-06	9.07e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.98e-06	8.86e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—IL6—acquired immunodeficiency syndrome	5.44e-06	8.05e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—ALB—acquired immunodeficiency syndrome	5.3e-06	7.85e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.29e-06	7.84e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.23e-06	7.75e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.13e-06	7.61e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—IL6—acquired immunodeficiency syndrome	5.02e-06	7.44e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.87e-06	7.22e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.86e-06	7.2e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—IL6—acquired immunodeficiency syndrome	4.81e-06	7.13e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—ALB—acquired immunodeficiency syndrome	4.62e-06	6.84e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—IL6—acquired immunodeficiency syndrome	4.44e-06	6.58e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—ALB—acquired immunodeficiency syndrome	4.35e-06	6.45e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.29e-06	6.35e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.51e-06	5.21e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.11e-06	4.61e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	2.85e-06	4.22e-05	CbGpPWpGaD
